Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US
Executive Summary
Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.
You may also be interested in...
US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience
Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.
After Recusal, Schnedar Leaving CDER Compliance Office
Cynthia Schnedar decides to leave several weeks after FDA determined that her husband's promotion could create conflicts of interest.
FDA Inspections Ombudsman Could Help Foreign Manufacturers
New ORA position intended to help get questions answered, but already being used to smooth inspection issues.